

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Mehrdad Abedi MD		POSITION TITLE Attending Physician/ Bone Marrow Transplantation Scientist, Department of Research	
eRA COMMONS USER NAME mabedi			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Tehran Univ. of Medical Sciences, Tehran/Iran		1985-1991	Medicine
Yale University/Bridgeport Hospital Program, Bridgeport, CT.		1996-1999	Internal Medicine Residency
University of Mass. Medical Center, Worcester, MA		1999- 7/2001	Hematology/Oncology Fellowship
Brown University/Roger Williams Hospital		7/2001- 7/2002	Hematology/Oncology Fellowship

A. Positions and Honors. List in chronological order previous positions, concluding with your present position. List any honors. Include present membership on any Federal Government public advisory committee.

Positions

1/6/92-12/29/93	Abadan Base Clinic, Abadan, Iran
1/12/94-9/1/95	Social Service, Ivan Hospital, Ivan, Iran
10/1/95-6/30/96	Clinical Research on Antiphospholipid Antibody, St. Mary Hospital, Waterbury, CT
7/1/96-6/30/99	Internal Medicine Resident, Yale University, Bridgeport Hospital
7/1/99-7/1/02	Hematology/Oncology fellowship, University of Mass. Medical Center
7/1/02-Current	Assistant professor of medicine , Roger Williams Hospital
10/1/06-Current	Director Stem Cell Laboratory, Cancer Center, Roger Williams Hospital

Honors and Awards

1985	Ranked 23 out of more than 600,000 High School graduates in Iranian National University Examination
1997 & 1998	Ranked 98th percentile in the United States Residency in-service exam
1998	5K Research grant awarded by Bridgeport Hospital
1998	Awarded for the best abstract in Bridgeport Hospital Annual Science Symposium
1999	Diplomate of Internal Medicine, The American Board of Internal Medicine
2002	ISEH travel award

B. Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in preparation.

Peer Reviewed Articles of Original Research

1. IJdo JW, Conti-Kelly AM, Greco P, **Abedi M**, Amos M, Provenzale JM, Greco TP, Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? *Lupus* 1999;8(2):109-15 1.
2. Lambert J-F, Colvin GA, Zhong S, Wang H, D'Hondt L, **Abedi M**, Frimberger AE, Stewart FM, Quesenberry PJ. H2 mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation. *Brit J Haematol* 2002.

3. Colvin GA, Lambert J-F, Carlson JE, McAuliffe CI, **Abedi M**, and Quesenberry PJ. Rhythmicity of engraftment and altered cell cycle kinetics of cytokine cultured murine marrow in simulated microgravity compared with static cultures. *In Vitro Cell Dev Biol-Anim.* 2002;in press
4. Quesenberry PJ, Stewart FM, Becker P, D'Hondt L, Frimberger A, Lambert JF, Colvin GA, Miller C, Heyes C, **Abedi M**, Dooner M, Carlson J, Reilly J, McAuliffe C, Stencel K, Ballen K, Emmons R, Doyle P, Zhong S, Wang H, Habibian H. Stem cell engraftment strategies. *Ann N Y Acad Sci.* 2001 Jun;938:54-61; discussion 61-2.
5. Colvin GA, Rathore R, Lambert J-F, **Abedi M**, Khorsand J, Kouttab N, Badiavas E, Lum LG, Quesenberry PJ, Eifenbein GJ. HLA-Haploidentical Stem Cell Infusions For Refractory Hematologic Malignancies: A Universal Outpatient Immunotherapeutic Approach In 100 cGy Treated Patients. Proceedings of the XIth International Symposium of Autologous Blood and Marrow Transplantation 2003; Edited by: Karel A. Dicke & Armand Keating, Carden Jennings Publishing Co., Ltd. December 2003.
6. Colvin GA, Lambert JF, Carlson JE, McAuliffe CI, **Abedi M**, Quesenberry PJ. Rhythmicity of engraftment and altered cell cycle kinetics of cytokine-cultured murine marrow in simulated microgravity compared with static cultures. *In Vitro Cell Dev Biol Anim.* 2002 Jun;38(6):343-351.
7. **Abedi M**, Greer D, Lambert J.F, Colvin G.A., Dooner M.S., McAuliffe C.I., Demers D and Quesenberry P.J. Tolerance induction by costimulator blockade in 100cGy treated hosts with varying degrees of genetic disparity . *Leukemia.* 2003 Sep;17(9):1871-9.
8. **Abedi M**, Quesenberry P. Hematopoietic Growth Factors. In: The Atlas of Clinical Hematology Hematology Atlas. Current Medicine Inc. 2003
9. Quesenberry PJ, Colvin GA, **Abedi M**, Lambert JF, Moore B, Demers D, Greer D, McAuliffe C, Dooner M, Lum LG, Badiavas E, Falanga V. The marrow stem cell: the continuum. *Bone Marrow Transplant.* 2003 Aug;32 Suppl 1:S19-22.
10. Quesenberry P, Colvin G, Lambert JF, **Abedi M**, Cerny J, Dooner M, Moore B, McAuliffe C, Demers D, Greer D, Parent A, Badiavas E, Lum L, Falanga V. Marrow stem cell potential within a continuum. *Ann N Y Acad Sci.* 2003 May;996:209-21.
11. Colvin G, Lambert JF, Hsieh C, **Abedi M**, Stewart F, Quesenberry Q: Murine Marrow Cellularity and the Concept of Stem Cell Competition Geographic and Quantitative Determinants in Stem Cell Biology. *J Exp. Med,* 2003.
12. Quesenberry PJ, Lambert JF, Colvin GA, Dooner M, McAuliffe C, **Abedi M**, Greer D, Falanga V, Badiavas E: The Stem Cell Continuum. Book-Publication "Stem Cells in Tissue Regeneration", edited by G. Steinhoff, M. Freund, V. Jansson, A. Rolfs. Presented at the Baltic Stem Cell Conference, University of Rostock, Germany, 2002.
13. Quesenberry PJ, **Abedi M**, Aliotta J, Colvin GA, Demers D, Dooner M, Greer D, Hebert H, Menon MK, Pimentel J, Paggioli D. Stem cell plasticity: an overview. *Blood Cell Mol Dis.* 2004;32:1-4.
14. Colvin GA, Lambert J-F, **Abedi M**, Dooner MS, Demers D, Moore BE, Greer D, Aliotta JM, Pimentel J, Cerny J, Lum LG, Quesenberry PJ. Differentiation Hotspots: The Deterioration of Hierarchy and Stochasm. *Blood Cell Mol Dis.* 2004;32:34-41.
15. **Abedi M**, Greer DA, Colvin GA, Demers DA, Dooner MS, Harpel JA, Pimentel J, Menon MK, Quesenberry PJ. Tissue injury in marrow transdifferentiation. *Blood Cell Mol Dis.* 2004;32:42-46
16. Dooner MS, Cerny J, Colvin GA, Demers D, Pimentel J, Greer DA, **Abedi M**, McAuliffe CI, Quesenberry PJ. Homing and conversion of murine hematopoietic stem cells to lung, *Blood Cell Mol Dis.* 2004;32:47-51.
17. Colvin GA, Lambert JF, **Abedi M**, Carlson JE, Dooner MS, Moore BE, Cerny J, Quesenberry PJ. Intrinsic hematopoietic stem cell/progenitor plasticity: Inversions. *J Cell Physiol* 2004;199:20-31.
18. Colvin GA, Lambert JF, **Abedi M**, Hsieh CC, Carlson JE, Stewart FM, Quesenberry PJ. Murine Marrow Cellularity and the Concept of Stem Cell Competition: Geographic and Quantitative Determinants in Stem Cell Biology. *Leukemia.* 2004; in press.
19. **Abedi M**, Eifenbein GJ. Novel approaches in the treatment of multiple myeloma. *Med Health R I.* 2003 Aug; 86(8): 231-5. Review.
20. **Abedi M**, Greer D.A, Colvin G.A., Demers D.A., Dooner M.S., Harpel J. A., Weier U, Lambert J.F., and Quesenberry P.J. Robust Conversion of Marrow Cells to Skeletal Muscle with Formation of Marrow Derived Muscle Cell Colonies: A Multifactorial Process. *Exp. Hem* in press.

21. ***Badiavas E**, ***Abedi M**, Butmarc J, Falanga V, Quesenberry PJ. Participation of bone marrow cells in cutaneous wound healing. *J Cell Physiol*. 2003 Aug;196(2):245-50.
22. Quesenberry PJ, Dooner G, Colvin G, **Abedi M**. Stem cell biology and the plasticity polemic. *Exp Hematol*. 2005 Apr;33(4):389-94.
23. Quesenberry PJ, Colvin G, **Abedi M**. Perspective: fundamental and clinical concepts on stem cell homing and engraftment: a journey to niches and beyond. *Exp Hematol*. 2005 Jan;33(1):9-19. Review.
24. **Abedi M**, Greer DA, Colvin GA, Demers DA, Dooner MS, Harpel JA, Weier HU, Lambert JF, Quesenberry PJ. Robust conversion of marrow cells to skeletal muscle with formation of marrow-derived muscle cell colonies: a multifactorial process. *Exp Hematol*. 2004 May;32(5):426-34.
25. Quesenberry PJ, Dooner G, Dooner M, **Abedi M**. Developmental biology: Ignoratio elenchi: red herrings in stem cell research. *Science*. 2005 May 20;308(5725):1121-2.
26. **Abedi M**, Greer DA, Foster BM, Colvin GA, Harpel JA, Demers DA, Pimentel J, Dooner MS, Quesenberry. Critical variables in the conversion of marrow cells to skeletal muscle. *Blood*. 2005 Aug 15;106(4):1488-94.
27. Aliotta JM, Keaney P, Passero M, Dooner MS, Pimentel J, Greer D, Demers D, Foster B, Peterson A, Dooner G, Theise ND, **Abedi M**, Colvin GA, Quesenberry PJ. Bone marrow production of lung cells: the impact of G-CSF, cardiotoxin, graded doses of irradiation, and subpopulation phenotype. *Exp Hematol*. 2006 Feb;34(2):230-41.
28. Quesenberry P, **Abedi M**, Dooner M, et al. The marrow cell continuum: stochastic determinism. *Folia Histochem Cytobiol*. 2005;43(4):187-90.
29. Quesenberry PJ, Colvin GA, **Abedi M**, Dooner G, Dooner M, Aliotta J, Keaney P, Luo L, Demers D, Peterson A, Foster B, Greer D. The stem cell continuum. *Ann N Y Acad Sci*. 2005 Jun;1044:228-35.
30. Aliotta JM, Keaney P, Passero M, Dooner MS, Pimentel J, Greer D, Demers D, Foster B, Peterson A, Dooner G, Theise ND, **Abedi M**, Colvin GA, Quesenberry PJ. Bone marrow production of lung cells: the impact of G-CSF, cardiotoxin, graded doses of irradiation, and subpopulation phenotype. *Exp Hematol*. 2006 Feb;34(2):230-41.
31. **Abedi M**, Greer DA, Foster BA, Wood K, Colvin GA, McLean SA, Dooner, MS, Johnson KW, Zomorodian T. Hematopoietic Stem Cells Participate in Muscle Regeneration. (2006) Accepted with Revision *British Journal of Hematology*.
32. Colvin GA, Dooner MS, Dooner GJ, Sanchez-Guijo FM, Demers DA, **Abedi M**, Ramanathan M, Chung S, Pascual S, Quesenberry PJ. Stem cell continuum: Directed differentiation hotspots. *Exp Hematol*. 2007 Jan;35(1):96-107.

***It is mentioned in the manuscript that the first and second authors had the same contribution to the paper**

- C. Research Support.** List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and your role (e.g. PI, Co-Investigator, Consultant) in the research project. Do not list award amounts or percent effort in projects.

Current:

1- Cell cycle related stem cell transdifferentiation.

Grant Period: 7/1/03-6/30/08

Mehrdad Abedi, MD (PI)

Agency: NHLBI

Type: 1KO8 HL072332-01

2- The New Stem Cell Biology (COBRE)

Grant Period: 9/30/03—9/29/08

Project 2: Myogenic Potential of of Bone Marrow Cells.

Mehrdad Abedi, MD (PI—Project 2)

Type: 1P20 RR018757-01

Principal Investigator/Program Director :

Falanga, Vincent

Agency: NIH – NCRR

3- Origin of Marrow Derived Fibroblasts in the Skin Sclerotic Process

Grant Period: 2/1/06 -12/30/06

Agency: RI Foundation

Mehrdad Abedi (PI)

Pending:

1- Role of MicroRNA in Post-Transcriptional Regulation of Utrophin

Grant Period: 12/1/07 – 11/30/9

Agency: NIH (1R21 AR054399-01)

Mehrdad Abedi, MD (PI)